Immunotherapy is revolutionizing cancer treatment. The majority of neoantigens arise from unique mutations that are not shared between individual patients, making neoantigen- directed immunotherapy a fully personalized treatment approach. Recent human clinical trials have demonstrated that personalized neoantigen vaccines are feasible, safe and immunogenic in cancer patients.
Personalised medicine starts with the biopsy of the patient’s tumour followed by the tumour analysis, sequencing, and selection of the tumour-specific mutations (Neoantigens). Once these neoantigens have been selected, BCN Peptides can take part in the process and start the GMP production of the desired peptides and perform the peptide pooling, as we are prepared to deliver peptides and pools for both ex-vivo and in-vivo approaches.
Our Peptide-based Personalised Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology to meet the unique requirements of neoantigens production. A dedicated and experienced team of chemists and doctors ensures full control of the processes.